Candriam S.C.A. Purchases 142,591 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Candriam S.C.A. boosted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 135.8% in the fourth quarter, HoldingsChannel reports. The firm owned 247,591 shares of the company’s stock after buying an additional 142,591 shares during the quarter. Candriam S.C.A.’s holdings in Spyre Therapeutics were worth $5,764,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Barclays PLC boosted its stake in Spyre Therapeutics by 64.7% in the third quarter. Barclays PLC now owns 105,467 shares of the company’s stock valued at $3,101,000 after acquiring an additional 41,424 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Spyre Therapeutics in the fourth quarter valued at about $290,000. Charles Schwab Investment Management Inc. boosted its stake in Spyre Therapeutics by 239.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 333,275 shares of the company’s stock valued at $9,802,000 after acquiring an additional 235,094 shares during the last quarter. Jane Street Group LLC boosted its stake in Spyre Therapeutics by 78.7% in the third quarter. Jane Street Group LLC now owns 20,641 shares of the company’s stock valued at $607,000 after acquiring an additional 9,090 shares during the last quarter. Finally, State Street Corp boosted its stake in Spyre Therapeutics by 9.4% in the third quarter. State Street Corp now owns 1,541,555 shares of the company’s stock valued at $45,337,000 after acquiring an additional 131,896 shares during the last quarter. 80.39% of the stock is owned by institutional investors.

Spyre Therapeutics Trading Down 4.9 %

Shares of SYRE stock opened at $19.49 on Friday. The stock has a market capitalization of $1.17 billion, a P/E ratio of -2.61 and a beta of 2.98. The firm’s 50 day moving average is $21.91 and its 200 day moving average is $26.55. Spyre Therapeutics, Inc. has a 12 month low of $17.24 and a 12 month high of $47.97.

Spyre Therapeutics (NASDAQ:SYRE) last posted its earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.08. On average, equities analysts predict that Spyre Therapeutics, Inc. will post -4.46 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $65.00 target price on shares of Spyre Therapeutics in a research note on Monday, January 13th. Robert W. Baird boosted their target price on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Finally, The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 18th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $54.83.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).